VBL's brain cancer candidate wins fast-track status from FDA

12/1/2013 | Globes (Israel)

The FDA granted fast-track designation to VBL Therapeutics' VB-111, its drug candidate for recurrent glioblastoma multiforme. The gene therapy, designed to be given as a simple IV infusion, was previously awarded orphan status in the U.S. and Europe. VB-111 is also under development for treatment of differentiated thyroid cancer and ovarian cancer.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ